Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 73% Improvement Relative Risk Improvement in dyspnea 38% Improvement in Ct score 22% Colchicine  Pourdowlat et al.  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 202 patients in Iran (March - September 2020) Lower hospitalization (p=0.0037) and improved recovery (p=0.025) c19early.org Pourdowlat et al., Phytotherapy Research, Feb 2022 Favors colchicine Favors control

Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial

Pourdowlat et al., Phytotherapy Research, doi:10.1002/ptr.7319
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000056 from 50 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
RCT 202 patients in Iran, 102 treated with colchicine, showing lower hospitalization and improved clinical outcomes with treatment.
risk of hospitalization, 72.8% lower, RR 0.27, p = 0.004, treatment 5 of 102 (4.9%), control 18 of 100 (18.0%), NNT 7.6.
relative improvement in dyspnea, 37.5% better, RR 0.62, p = 0.03, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.
relative improvement in Ct score, 22.4% better, RR 0.78, p = 0.048, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pourdowlat et al., 2 Feb 2022, Randomized Controlled Trial, Iran, peer-reviewed, 18 authors, study period 26 March, 2020 - 30 September, 2020.
This PaperColchicineAll
Efficacy and safety of colchicine treatment in patients with COVID ‐19: A prospective, multicenter, randomized clinical trial
Guitti Pourdowlat, Fatemeh Saghafi, Abolfazl Mozafari, Adeleh Sahebnasagh, Atefeh Abedini, Mohsen Nabi Meybodi, Ali Salehi Nezamabadi, Seyed Ruhollah Mousavinasab, Arda Kiani, Hanieh Raji, Nadia Soltani, Mehdi Gholmzadeh Baeis, Esmaeil Eidani, Abdolrahim Sadeghi Yakhdani, Fatemeh Movaseghi, Solomon Habtemariam, Zohreh Akhoundi Meybodi, Mohsen Gholinataj Jelodar
Phytotherapy Research, doi:10.1002/ptr.7319
Colchicine has shown clinical benefits in the management of COVID-19 via its antiinflammatory effect. However, the exact role of colchicine in COVID-19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID-19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3-day course of 0.5 mg colchicine followed by a 12-day course of 1 mg colchicine in combination with standard care or a 15-day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or
CONFLICT OF INTEREST The authors declare that they have no conflicts of interest regarding the publication of this paper. AUTHOR CONTRIBUTIONS Guitti
References
Arcanjo, Logullo, Menezes, Giangiarulo, Dos Reis et al., The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19), Scientific Reports
Beheshtian, Izadi, Kriegshauser, Kahrizi, Mehr et al., Prevalence of common MEFV mutations and carrier frequencies in a large cohort of Iranian populations, Journal of Genetics
Davatchi, Shahram, Chams-Davatchi, Shams, Nadji et al., Behcet's disease in Iran: Analysis of 6500 cases
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial, JAMA Network Open
Demidowich, Davis, Dedhia, Yanovski, Colchicine to decrease NLRP3-activated inflammation and improve obesityrelated metabolic dysregulation, Medical Hypotheses
Dupuis, Sirois, Rhéaume, Nguyen, Clavet-Lanthier et al., Colchicine reduces lung injury in experimental acute respiratory distress syndrome, PLoS One
Fiorucci, Lucantoni, Paone, Zotti, Li Bianchi et al., Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: Comparison of three currently available therapeutic regimens, European Review for Medical and Pharmacological Sciences
Francone, Iafrate, Masci, Coco, Cilia et al., Chest CT score in COVID-19 patients: Correlation with disease severity and short-term prognosis, European Radiology
Freeman, Swartz, Targeting the NLRP3 inflammasome in severe COVID-19, Frontiers in Immunology
George, Wells, Jenkins, Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy, The Lancet Respiratory Medicine
Jain, Effect of COVID-19 on the organs, Cureus
Jimeno, Ventura, Castellano, García-Adasme, Miranda et al., Prognostic implications of neutrophil-lymphocyte ratio in COVID-19, European Journal of Clinical Investigation
Kommoss, Schwab, Tavernar, Schreck, Wagner et al., The pathology of severe COVID-19-related lung damage: Mechanistic and therapeutic implications, Deutsches Ärzteblatt International
Liu, Lei, Liao, Shi, Li et al., Semiquantitative analysis for the dynamic chest CT imaging features from onset to recovery in severe and critical COVID-19, Radiology of Infectious Diseases
Mansouri, Marjani, Tabarsi, Garnier, Mansouri, Successful treatment of Covid-19 associated cytokine release syndrome with colchicine. A case report and review of literature, Immunological Investigations
Mo, Jian, Su, Chen, Peng et al., Abnormal pulmonary function in COVID-19 patients at time of hospital discharge, European Respiratory Journal
Nasiripour, Zamani, Farasatinasab, Can colchicine as an old anti-inflammatory agent be effective in COVID-19?, Journal of Clinical Pharmacology
Pan, Ye, Sun, Gui, Liang et al., Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia, Radiology
Reddel, Pennings, Curnow, Chen, Kritharides, Procoagulant effects of low-level platelet activation and its inhibition by colchicine, Thrombosis and Haemostasis
Robertson, Payet, Martinez, Barraclough, Celermajer et al., Colchicine acutely suppresses the NLRP3 Inflammasome in acute coronary syndrome patients monocytes, Circulation
Sahebnasagh, Saghafi, Safdari, Khataminia, Sadremomtaz et al., Neutrophil Elastase inhibitor (Sivelestat), may be a promising therapeutic option for Management of Acute Lung Injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19, Journal of Clinical Pharmacy and Therapeutics
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection, Canadian Journal of Infectious Diseases and Medical Microbiology
Scarsi, Piantoni, Colombo, Air O, Richini et al., Association between treatment with colchicine and improved survival in a single-Centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Annals of the Rheumatic Diseases
Seçkin, Bütün, Bas, Takcı, Kalkan, Effects of colchicine treatment on mean platelet volume and the inflammatory markers in recurrent aphthous stomatitis, Journal of Dermatological Treatment
Slobodnick, Shah, Krasnokutsky, Pillinger, Update on colchicine, Rheumatology
Song, Liu, Shi, Chu, Zhang et al., SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19, Gut
Spinner, Gottlieb, Criner, Opez, Cattelan et al., Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial, JAMA
Tardif, Bouabdallaoui, L'allier, Gaudet, Shah et al., Efficacy of colchicine in nonhospitalized patients with COVID-19, Medrxiv, doi:10.1101/2021.01.26.21250494
Vaidya, Tucker, Kurup, Khandkar, Pandzic et al., Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention, Journal of the American Heart Association
Yurdakul, Mat, Tüzün, Özyazgan, Hamuryudan et al., A double-blind trial of colchicine in Behçet's syndrome, Arthritis and Rheumatism
Zhang, Ma, Shanahan, Munroe, Horn et al., Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial, BMC Medical Informatics and Decision Making
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit